Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates

Core Insights - Viridian Therapeutics, Inc. (VRDN) reported a quarterly loss of $1.15 per share, which was worse than the Zacks Consensus Estimate of a loss of$1.11, marking an earnings surprise of -3.60% [1] - The company generated revenues of $0.09 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 4.88$0.07 million [2] - The stock has underperformed the market, gaining about 18% year-to-date compared to the S&P 500's gain of 25.8% [3] Financial Performance - Over the last four quarters, Viridian Therapeutics has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$1.03 on revenues of$0.09 million, and for the current fiscal year, it is -$3.94 on revenues of$0.21 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Viridian Therapeutics belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]